Prenetics Global Ltd
PRE7.965USD
-0.035-0.44%
Market hours （ET）Quotes delayed by 15 min
102.31MMarket Cap
LossP/E TTM
More Details of Prenetics Global Ltd Company
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Company Info
Ticker SymbolPRE
Company namePrenetics Global Ltd
IPO dateJul 06, 2021
CEOMr. Joel Neoh
Number of employees285
Security typeOrdinary Share
Fiscal year-endJul 06
AddressUnit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
City
Stock exchangeLondon Stock Exchange
CountryHong Kong
Postal code- -
Phone85222109588
Websitehttps://ir.prenetics.com/
Ticker SymbolPRE
IPO dateJul 06, 2021
CEOMr. Joel Neoh
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
Ms. Jordan Lemerande
Ms. Jordan Lemerande
Vice President - Product Development
Vice President - Product Development
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Ms. Wing Kwan (Winnie) Chiu
Ms. Wing Kwan (Winnie) Chiu
Independent Director
Independent Director
--
--
Mr. Joel Neoh
Mr. Joel Neoh
Chief Consumer Officer, Chief Executive Officer of CircleDNA
Chief Consumer Officer, Chief Executive Officer of CircleDNA
--
--
Mr. Alan Thomas
Mr. Alan Thomas
Vice President, Supply Chain & Operations
Vice President, Supply Chain & Operations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
Ms. Jordan Lemerande
Ms. Jordan Lemerande
Vice President - Product Development
Vice President - Product Development
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Hong Kong
14.27M
46.59%
Taiwan
7.09M
23.16%
The United States
5.51M
18.00%
United Kingdom
2.78M
9.08%
Rest of the world
972.00K
3.17%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 9
Updated: Wed, Jul 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dennis (Lo Yuk Ming)
8.41%
Genetel Bioventures Ltd
5.36%
Lawrence (Tzang Chi Hung)
4.69%
Eastspring Investments (Singapore) Limited
3.74%
Aspex Management (HK) Limited
3.02%
Other
74.78%
Shareholders
Shareholders
Proportion
Dennis (Lo Yuk Ming)
8.41%
Genetel Bioventures Ltd
5.36%
Lawrence (Tzang Chi Hung)
4.69%
Eastspring Investments (Singapore) Limited
3.74%
Aspex Management (HK) Limited
3.02%
Other
74.78%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.52%
Investment Advisor
6.72%
Corporation
5.36%
Hedge Fund
3.13%
Research Firm
2.91%
Investment Advisor/Hedge Fund
0.06%
Other
67.31%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
30
3.75M
32.70%
-1.26M
2025Q1
31
3.72M
35.24%
-295.48K
2024Q4
35
3.71M
34.90%
-336.29K
2024Q3
37
3.69M
34.65%
-448.54K
2024Q2
38
3.76M
35.34%
-535.47K
2024Q1
88
5.56M
55.93%
+1.27M
2023Q4
94
4.17M
42.91%
+30.90K
2023Q3
99
4.01M
43.06%
+108.37K
2023Q2
98
3.11M
36.85%
-918.88K
2023Q1
94
3.14M
40.86%
+44.13K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dennis (Lo Yuk Ming)
962.96K
8.41%
--
--
Apr 24, 2025
Genetel Bioventures Ltd
613.79K
5.36%
--
--
Sep 30, 2024
Lawrence (Tzang Chi Hung)
537.10K
4.69%
--
--
Apr 24, 2025
Eastspring Investments (Singapore) Limited
427.96K
3.74%
--
--
Mar 31, 2025
Aspex Management (HK) Limited
346.15K
3.02%
--
--
Mar 31, 2025
Nomura Securities Co., Ltd.
333.53K
2.91%
+10.58K
+3.27%
Mar 31, 2025
Pacific Alliance Group Asset Management Limited
290.25K
2.53%
-1.00
-0.00%
Nov 27, 2023
Chun (Lo Hoi)
162.62K
1.42%
--
--
Apr 24, 2025
UBS Financial Services, Inc.
26.33K
0.23%
-64.00
-0.24%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 01, 2023
Merger
15<1
Nov 01, 2023
Merger
15<1
Nov 01, 2023
Merger
15<1
Nov 01, 2023
Merger
15<1
Date
Type
Ratio
Nov 01, 2023
Merger
15<1
Nov 01, 2023
Merger
15<1
Nov 01, 2023
Merger
15<1
Nov 01, 2023
Merger
15<1
